drugset
Drugs / Luprolide
last change Jun 2025 re-read 2 minutes ago

Luprolide

also known as Lucrin Depot PDS inj
Developed for
castration-resistant prostate carcinoma
Investigated by
Asan Medical Center

Trials 1 · a red edge is where a trial was stopped

today NCT01487902 · Ph 2
20112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01487902 Jul 2010 → Oct 2013 castration-resistant prostate carcinoma Asan Medical Center Unknown No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT05873192 Background Jun 2025 → Dec 2026 expected prostate cancer M.D. Anderson Cancer Center Recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Luprolide “Luprolide 11.25 mg long-acting depo (Lucrin Depot PDS inj®) every 12 weeks SC wit Docetaxel-prednisolone (TAX327 regimen)” NCT01487902 ↗
1

NCT05873192 ↗
Known as Lucrin Depot PDS inj “Luprolide 11.25 mg long-acting depo (Lucrin Depot PDS inj®) every 12 weeks SC wit Docetaxel-prednisolone (TAX327 regimen)” NCT01487902 ↗
Route Subcutaneous “every 12 weeks SC” NCT01487902 ↗